Mankind Pharma shares jump 11% after robust Q2 earnings and upbeat broker forecasts

Mankind Pharma’s shares surged 6.5% to ₹2,451.95 on the BSE, extending a rally that lifted the stock 11% in two sessions after the firm released its Q2 FY27 results. The company posted a 37.7% year-on-year rise in consolidated net profit, reaching ₹716 crore, while revenue climbed 17.3% to ₹4,338 crore, largely on domestic sales of chronic-care drugs. EBITDA rose 27.2% to ₹1,175 crore, with margins improving to 27.1%.

Brokerages such as JM Financial Institutional Securities and Systematix Institutional Research upgraded their outlooks, citing stronger volume, export performance and a favorable domestic revival, and set new target prices of ₹2,638 and higher. Jefferies increased its EBITDA forecast by 3%, valued the company at 22× Dec-28 EBITDA and retained a buy rating. Management reaffirmed its FY27 EBITDA margin guidance and highlighted continued R&D investment.